Dupilumab elicits a favorable response in type-2 inflammatory comorbidities of severe atopic dermatitis

BACKGROUND: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. CASE PRESENTATION: We report on effects of dupilumab in a patient with seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Nettis, Eustachio, Masciopinto, Lucia, Di Leo, Elisabetta, De Candia, Nicola, Albanesi, Marcello, Di Bona, Danilo, Quaranta, Nicola, Macchia, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207639/
https://www.ncbi.nlm.nih.gov/pubmed/34134707
http://dx.doi.org/10.1186/s12948-021-00144-x
Descripción
Sumario:BACKGROUND: This case is the first report describing rapid, successful treatment of severe atopic dermatitis (AD) and comorbid type-2 inflammatory diseases in the same patient, with dupilumab treatment, with no side-effects. CASE PRESENTATION: We report on effects of dupilumab in a patient with severe AD, a long-standing history of a mild, perennial allergic rhino-conjunctivitis, moderate asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). CONCLUSIONS: Patients suffering from AD, asthma, allergic rhinitis and CRSwNP may be eligible for dupilumab single treatment that is possibly advantageous also from the pharmaco-economic standpoint.

Ejemplares similares